Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Aprea Therapeutics Inc shares valued at $25,000 were purchased by Duey Marc on Dec 10 ’25. At $1.17 per share, Duey Marc acquired 21,459 shares. The insider’s holdings grew to 256,155 shares worth approximately $0.22 million following the completion of this transaction.
Also, Hamill John P. purchased 5,000 shares, netting a total of over 5,825 in proceeds. Following the buying of shares at $1.17 each, the insider now holds 27,733 shares.
Before that, Gilad Oren had added 5,500 shares to its account. In a trade valued at $10,110, the President/CEO bought Aprea Therapeutics Inc shares for $1.84 each. Upon closing the transaction, the insider’s holdings increased to 5,500 shares, worth approximately $0.29 million.
As published in a research note from Robert W. Baird on December 28, 2020, Aprea Therapeutics Inc [APRE] has been rated down from an Outperform to a Neutral. Analysts at Berenberg started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. Earlier on June 22, 2020, H.C. Wainwright initiated its rating. Their recommendation was “a Neutral” for APRE stock.
Analyzing APRE Stock Performance
On last trading session, Aprea Therapeutics Inc [NASDAQ: APRE] plunged -4.16% to $0.85. The stock’s lowest price that day was $0.8427, but it reached a high of $0.914 in the same session. During the last five days, there has been a drop of approximately -10.37%. Over the course of the year, Aprea Therapeutics Inc shares have dropped approximately -74.69%. Shares of the company reached a 52-week high of $5.0000 on 01/03/25 and a 52-week low of $0.8400 on 12/31/25.
Support And Resistance Levels for Aprea Therapeutics Inc (APRE)
According to the 24-hour chart, there is a support level at 0.8240, which, if violated, would cause prices to drop to 0.7950. In the upper region, resistance lies at 0.8980. The next price resistance is at 0.9430. RSI (Relative Strength Index) is 29.86 on the 14-day chart, showing oversold technical sentiment.
Is Aprea Therapeutics Inc subject to short interest?
Stocks of Aprea Therapeutics Inc saw a sharp steep in short interest on 2025-12-15 dropping by 28699.0 shares to 34578.0. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 63277.0 shares. A decline of -83.0% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.48 of the overall float, the days-to-cover ratio (short ratio) decline to 0.48.
Which companies own the most shares of Aprea Therapeutics Inc (APRE)?
In spite of this, 6 analysts ranked Aprea Therapeutics Inc stock as Buy at the end of 2026. On April 21, 2020, Robert W. Baird assigned a price target of “an Outperform” to the stock and initiated coverage with a $45.
